- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued over 20% based on DCF
U.S. Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
24
6 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
24 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$818.86 | 1.6% | 34.1% | US$749.6b | US$993.37 | PE88.1x | E29.4% | 0.6% | ||
JNJ | US$152.64 | -3.6% | 3.4% | US$373.3b | US$174.62 | PE24.9x | E10.3% | 3.2% | ||
TMO | US$540.75 | -3.6% | 17.7% | US$209.2b | US$656.23 | PE33.7x | E11.8% | 0.3% | ||
AMGN | US$298.84 | -6.4% | 10.7% | US$173.0b | US$333.41 | PE38x | E19.1% | 3.0% | ||
VRTX | US$490.00 | -2.0% | 32.5% | US$129.2b | US$511.90 | PS11.9x | E47.2% | n/a | ||
ZTS | US$173.96 | -0.7% | 0.8% | US$79.5b | US$214.78 | PE32.3x | E9.9% | 1.0% | ||
IQV | US$213.57 | 0.3% | 6.5% | US$39.4b | US$255.70 | PE27.6x | E13.8% | 0% | ||
BGNE | US$193.64 | -6.9% | -3.9% | US$21.8b | US$276.99 | PS6.6x | E55.4% | n/a | ||
ICLR | US$212.27 | -6.2% | -20.5% | US$17.5b | US$283.00 | PE23.4x | E13.7% | n/a | ||
AVTR | US$21.79 | -4.3% | 15.7% | US$15.2b | US$27.31 | PE47.9x | E35.9% | n/a | ||
CRL | US$215.94 | 14.4% | 21.1% | US$11.3b | US$219.17 | PE26.7x | E11.7% | n/a | ||
MEDP New | US$360.81 | 9.9% | 27.9% | US$11.3b | US$349.32 | PE30.6x | E10.9% | n/a | ||
QGEN | US$43.23 | -1.6% | 6.0% | US$9.8b | US$50.66 | PE103.4x | E33.6% | 3.0% | ||
ACLX New | US$100.48 | 15.3% | 111.7% | US$5.8b | US$111.69 | PS34.9x | E-15.1% | n/a | ||
SHC | US$15.54 | 0.8% | 12.6% | US$4.5b | US$17.43 | PE62.4x | E44.9% | n/a | ||
SYNH | US$42.98 | 0.6% | -8.8% | US$4.5b | US$42.63 | PE62.6x | E33.7% | n/a | ||
PBH New | US$81.63 | 9.2% | 37.3% | US$4.0b | US$85.29 | PE19.6x | E5.3% | n/a | ||
VCYT | US$38.24 | 6.4% | 51.4% | US$3.0b | US$41.13 | PS7x | E46.5% | n/a | ||
NAMS New | US$24.76 | 29.3% | 170.6% | US$2.3b | US$37.95 | PS68.1x | E28.3% | n/a | ||
IMCR New | US$33.75 | 2.3% | -31.1% | US$1.7b | US$68.10 | PS5.7x | E5.8% | n/a | ||
MYGN | US$16.17 | -8.2% | -3.8% | US$1.6b | US$25.69 | PS1.8x | E64.2% | n/a | ||
PAHC | US$25.06 | 9.7% | 146.4% | US$1.0b | US$18.40 | PE58.3x | E60.0% | 1.9% | ||
MLAB | US$112.40 | -7.0% | 20.1% | US$646.0m | US$140.00 | PS2.7x | E124.8% | 0.6% | ||
ANIX New | US$3.25 | -9.0% | 13.6% | US$107.2m | US$8.50 | PB4.8x | E9.5% | n/a |
Page 1 of 1